



Health Technology Review	
Technology Ref.:	HTA-24004
Technology Name/Version/Model:	DeepCatch- Version.1.2.0
Approvals by International Bodies:	FDA (US), MFDS (Republic of Korea)
Company name:	MEDICAL IP Co., Ltd.
Agent in UAE:	iConsult Trading Consultancy LLC
Email:	life@medicalip.com

Short Description of the Technology:	Using artificial intelligence (AI), we quantitatively analyze the body composition within medical imaging (CT, MRI), providing a detailed report on the current physical condition of the entire body. Whole body composition encompasses: skin, bones (including T1-T12, L1-L5), central nervous system, internal organs, liver, spleen, subcutaneous fat, visceral fat, and measurements for muscle area, volume, and HU values. DeepCatch utilizes CT and MRI images to quantitatively analyze these whole-body compositions, presenting them in standardized numerical values. This information can assist healthcare professionals in diagnosing specific conditions such as muscle atrophy, osteoporosis, obesity, and more, serving as a valuable diagnostic aid.
---	--

Health Technology Assessment Team Recommendation:	Approve
Summary of Review:	
It seamlessly detects and monitors conditions such as sarcopenia, visceral obesity, and adipopenia. It facilitates early intervention in metabolic diseases with an accuracy rate of 98%. AI based automatic analysis of body composition and quantitative information for skin, bone, muscle, visceral and subcutaneous fat, organs. It is used for automatic segmentation of whole body.	
Advantages	Disadvantages
Comprehensive and accurate body composition analysis.	Standardization graph is currently based on Asian and American data. Consequently patients from other regions may encounter confusion as the standard graph not align with their region
AI-enhanced precision and reliability generated reports	
Provides standardized quantitative data	
Predictive capabilities for patient outcomes and disease progression.	
The Technology is FDA approved in June	


2023 and Korea ministry of food and drug safety (M).FDS	
No evidence of recalls or safety alerts.	
Comprehensive and accurate body composition analysis.	

We recommend an **approval using this technology** for Market entry with the following conditions:

1. DeepCatch- Version.1.2.0.
2. Establishing a proper quality monitoring process and reporting of any adverse events or unwarranted consequences including safety issues of employees.
3. Provision of regular updates and reports about the product to DOH upon request.

Moreover, DOH has the right to stop the product at any stage if deemed necessary, initial conditions and any subsequent conditions must be satisfied before obtaining final approval. Failure to do so will reflect in provoking the approval.

Technology Image



Population, setting and intended user for Technology “DeepCatch- Version.1.2.0.me”

- **Population/ Intended User;**
 - Patients with chronic conditions or undergoing cancer treatment.
 - Individuals at risk for diseases like osteoporosis or muscle atrophy.
- **To be performed by:**
 - By Radiologist
- **Clinical Setting:**
 - Utilize this technology in oncology centers and imaging departments
- **Condition of use:**



- Successful Clinical Validation of Prognostic Predictions for Specific Conditions (Muscle Atrophy, Osteoporosis, Hepatitis B, Metabolic Syndrome, obesity, etc.)
- Lung cancer
- Cervical Cancer.
- Ovarian cancer.
- Sarcopenia.
- Diabitise.
- **Exclusion criteria:**
 - Pregnant women